Enanta Pharmaceuticals (ENTA) Payables (2012 - 2026)

Enanta Pharmaceuticals' Payables history runs 15 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• Quarterly Payables fell 8.26% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 8.26% YoY) and the FY2025 annual result came in at $1.9 million, down 75.66% from the prior year.
• Payables was $4.4 million for Q1 2026 at Enanta Pharmaceuticals, up from $1.9 million in the prior quarter.
• Across five years, Payables topped out at $11.8 million in Q1 2023 and bottomed at $1.2 million in Q2 2022.
• A 5-year average of $5.7 million and a median of $4.8 million in 2025 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables sank 78.88% — and 2023, when it jumped 537.11%.
• Enanta Pharmaceuticals' Payables stood at $4.4 million in 2022, then surged by 114.29% to $9.3 million in 2023, then sank by 49.32% to $4.7 million in 2024, then tumbled by 60.11% to $1.9 million in 2025, then surged by 131.46% to $4.4 million in 2026.
• Business Quant data shows ENTA's Payables at $4.4 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.